Assessment of baseline bone turnover marker levels and response to risedronate treatment: Data from a Japanese phase III trial

BACKGROUND: Risedronate increases bone mineral density (BMD) and reduces fracture risk, but treatment response may depend on the baseline state of bone turnover. Data regarding the selection of therapeutic drugs or the prediction of therapeutic effects with baseline levels of bone turnover markers (...

Descripción completa

Detalles Bibliográficos
Autores principales: Mawatari, Taro, Ikemura, Satoshi, Matsui, Gen, Iguchi, Takahiro, Mitsuyasu, Hiroaki, Kawahara, Shinya, Maehara, Masayuki, Muraoka, Ryoichi, Iwamoto, Yukihide, Nakashima, Yasuharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7240327/
https://www.ncbi.nlm.nih.gov/pubmed/32462056
http://dx.doi.org/10.1016/j.bonr.2020.100275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7240327/
https://www.ncbi.nlm.nih.gov/pubmed/32462056
http://dx.doi.org/10.1016/j.bonr.2020.100275

Ejemplares similares